The current study intended to explore how ERBB3 mediates the PI3K/AKT/mTOR pathway and changes the tumor immune microenvironment to affect the EMT status of cervical cancer, which may provide further understanding of MMPs involved in immunotherapy. The gene discussed is PIK3CA; the disease is neoplasm.